Biwalirudyna może zmienić strategiȩ w kardiologii interwencyjnej umożliwiaja̧c wykonanie wybranych przezskórnych zabiegów, zarówno wieńcowych jak i obwodowych, w trybie ambulatoryjnym

Translated title of the contribution: Bivalirudin can change strategy in interventional cardiology allowing one day discharge after elective percutaneous coronary and peripheral interventions

Barbara K. Wiernek, R. Stefan Kiesz

Research output: Contribution to journalReview article

Abstract

Bivalirudin is a 20 amino acid polypeptide hirudin analog and one of the direct thrombin inhibitors. It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins in the settings of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Bivalirudin displays bivalent and reversible binding to the thrombin molecule, inhibiting its action. Results of multiple clinical trials to date suggest bivalirudin with provisional IIb/IIIa antagonists provides consistent results across the full spectrum of ACS, with similar or noninferior protection from ischemic events and significantly reduces bleeding complications compared with heparin with glycoprotein (GP) IIb/IIIa inhibitors. Bivalirudin presents the unique pharmacokinetic profile, very quick onset and short half-life what potentially can change interventional cardiology and enable outpatient interventions on elective cases. This article reviews the use of bivalirudin and clinical trial outcomes to date.

Translated title of the contributionBivalirudin can change strategy in interventional cardiology allowing one day discharge after elective percutaneous coronary and peripheral interventions
Original languagePolish
Pages (from-to)45-48
Number of pages4
JournalFarmaceutyczny Przeglad Naukowy
Volume7
Issue number5
StatePublished - Aug 9 2010

Keywords

  • Acute coronary syndrome (ACS)
  • Bivalirudin
  • Direct thrombin inhibitor (DTI)
  • Percutaneous coronary intervention (PCI)

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Bivalirudin can change strategy in interventional cardiology allowing one day discharge after elective percutaneous coronary and peripheral interventions'. Together they form a unique fingerprint.

  • Cite this